10517713

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:25:00 ON 24 MAY 2008

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:25:28 ON 24 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 23 May 2008 (20080523/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=>
Uploading C:\Program Files\Stnexp\Queries\10517713.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 17:25:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2000 TO ITERATE

100.0% PROCESSED 2000 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L2 2 SEA SSS FUL L1

L3 1 L2

=> d ibib abs hitstr

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1006952 CAPLUS
DOCUMENT NUMBER: 140:59517
TITLE: Preparation of 2,5-disubstituted 3-mercaptopentanoic acids as carboxypeptidase U inhibitors
INVENTOR(S): Polla, Magnus
PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106420	A1	20031224	WO 2003-SE970	20030610

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2488606	A1	20031224	CA 2003-2488606		20030610
AU 2003241260	A1	20031231	AU 2003-241260		20030610
AU 2003241260	B2	20070426			
BR 2003011384	A	20050315	BR 2003-11384		20030610
EP 1532111	A1	20050525	EP 2003-730987		20030610
EP 1532111	B1	20070808			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1662504	A	20050831	CN 2003-813840		20030610
JP 2005533064	T	20051104	JP 2004-513253		20030610
NZ 536814	A	20061130	NZ 2003-536814		20030610
AT 369342	T	20070815	AT 2003-730987		20030610
ES 2289297	T3	20080201	ES 2003-730987		20030610
NO 2004005051	A	20050113	NO 2004-5051		20041119
IN 2004DN03722	A	20070302	IN 2004-DN3722		20041124
ZA 2004009955	A	20060830	ZA 2004-9955		20041208
US 20050176780	A1	20050811	US 2004-517713		20041210
MX 2004PA12604	A	20050323	MX 2004-PA12604		20041214
HK 1077296	A1	20071109	HK 2005-109105		20051014
PRIORITY APPLN. INFO.:			SE 2002-1837	A	20020614
			WO 2003-SE970	W	20030610

OTHER SOURCE(S): MARPAT 140:59517

AB The title compds. R1(CH2)2CH(SH)CH(CO2H)CH2R2 [I; R1 = (un)substituted Ph, naphthyl, pyridinyl, etc.; R2 = aminopyridinyl, aminothiazolyl, 3-azabicyclo[3.2.1]octyl] which inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases where inhibition of carboxypeptidase U is beneficial, were prepared E.g., a 4-step synthesis of 2-[(6-aminopyridin-3-yl)methyl]-5-(1,1'-biphenyl-3-yl)-3-mercaptopentanoic acid (starting from 3-iodo-1,1'-biphenyl), was given. Biol. data was given for 13 exemplified compds. I. In further aspects, the invention relates to pharmaceutical compns. containing at least one compound I.

IT 637300-48-2P 637300-49-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,5-disubstituted 3-mercaptopentanoic acids as carboxypeptidase U inhibitors)

RN 637300-48-2 CAPLUS

CN 3-Pyridinepropanoic acid, 6-amino-α-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-1-mercaptopropyl]- (CA INDEX NAME)



RN 637300-49-3 CAPLUS
CN 3-Pyridinepropanoic acid, 6-amino-α-[3-(3-chlorophenyl)-1-mercaptopropyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT